5 Top Gainers In Healthcare Sector (OTLK, NEPT, EOLS...)

pharmaup july18

The following are some of today's top gainers in the pharma/biotech sector.

1. Outlook Therapeutics Inc. (OTLK)

Gained 34.87% to close Thursday's (Jul.18) trading at $2.63.

News: Analysts from H.C. Wainwright have given Outlook Therapeutics a "Buy" rating, with an estimated price target of $8.


The Company's lead product candidate is ONS-5010, which is under two phase III clinical trials for wet age-related macular degeneration, dubbed ONS-5010-001 and ONS-5010-002.

Enrollment in the ONS-5010-001 study is nearly complete while full enrollment in the ONS-5010-002 study is expected to occur in calendar Q4 2019.

The Company, which had cash of $0.2 million at March 31, 2019, raised net proceeds of approximately $26.2 million in April of this year.

2. Neptune Wellness Solutions Inc. (NEPT) (NEPT.TO)

Neptune Wellness is involved in cannabinoids extraction, formulation, and turnkey packaging solutions.

Gained 16.77% to close Thursday's trading at $5.71.

News: The Company has completed a private placement with both existing and new institutional investors, led by Perceptive Advisors, resulting in gross proceeds of US$41.4 million.

John Moretz, Chairman of the Board, and Michael Cammarata, President, and CEO of Neptune invested US$5.0 million in the aggregate as part of this Offering. Upon closing of the Offering, the Company issued an aggregate of 9.41 million common shares of the Company at a purchase price of US$4.40 per share.

3. Acasti Pharma Inc. (ACST)

Acasti is focused on the research, development, and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia (HTG).

Gained 15.33% to close Thursday's trading at $1.58.

News: No news

Clinical Trials and Near-term Catalysts:

-- The Company's lead product candidate CaPre for the treatment of severe hypertriglyceridemia is under two phase III trials, dubbed TRILOGY 1 and TRILOGY 2.
The topline results for the primary endpoint of lowering triglycerides for TRILOGY 1 are expected in December 2019 and for TRILOGY 2 in January 2020.

4. Alpine Immune Sciences Inc. (ALPN)

Alpine Immune is a clinical-stage immunotherapy company developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases.

Gained 13.58% to close Thursday's trading at $4.60.

News: No news

Clinical Trials:

A first-in-human Phase I study evaluating the safety and tolerability of single- and multiple-ascending intravenous and subcutaneous doses of ALPN-101 in healthy volunteers is underway. ALPN-101 is the Company's lead autoimmune/inflammatory disease program.

5. Evolus Inc. (EOLS)

Evolus is a medical aesthetics company.

Gained 13.58% to close Thursday's trading at $4.60.

News: No news

Near-term Catalyst:

The Company's marketing authorization application for Nuceiva in Europe awaits the final decision from the European Commission. On April 26, 2019, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Nuceiva.

Nuceiva is being evaluated by the EMA for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines). Nuceiva was approved in the U.S under brand name Jeuveau in February of this year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT